People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This includes Wegovy (the weight-loss dose of Ozempic, or semaglutide) and Mounjaro (one of the brand names for tirzepatide).
England subsidizes drugs like Ozempic for weight loss. Could Australia follow? Read More »
This Medical News article discusses safety concerns around compounded semaglutide and tirzepatide, including how clinicians can help prevent dosing errors.
Are Compounded GLP-1 Drugs Safe? Read More »
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms.
Study finds GLP-1 receptor agonists target fat over muscle for weight loss Read More »
(MedPage Today) — In older adults with diabetes, GLP-1 receptor agonists were tied to a slightly lower risk for depression compared with one diabetes drug class but not another, a target emulation trial using Medicare data found.
Among 13,711…
GLP-1 Receptor Agonists for Diabetes Tied to Slightly Lower Depression Risk Read More »
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms. A research team assessed the impact of GLP-1 receptor agonist in weight loss through genetic studies, aiming to understand whether the use of these medications reduces weight due to muscle or fat mass loss. This genetic study revealed that GLP-1 receptor agonists reduce weight by reducing more fat mass than muscle mass.
People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye condition that affects the optic nerve, a new study says.
Ozempic, Wegovy linked to potential vision loss Read More »
A doctor from the University of Palermo in Italy has published a case study of an adult cocaine user who experienced reduced withdrawal symptoms when given GLP-1 therapy. In the case study published in the Journal of Medical Case Reports, Doctor Vincenzo Maria Romeo reports on the treatment of an obese adult male patient with a history of cocaine abuse and how he responded to GLP-1 therapy.
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within one year. Discontinuation rates were significantly higher and reinitiation rates were significantly lower for patients without type 2 diabetes.
Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds Read More »
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings. However, over the past few years, these medications have become popular due to their weight loss and weight management benefits. Dr. Saundra Nguyen, assistant professor of internal medicine at Baylor College of Medicine, explains the side effects of GLP-1s.
What are the side effects of GLP-1 medications? A researcher explains Read More »
